OBJECTIVES: Atherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an optimal pharmacologic approach has not yet been established. The aim of this study is to compare the efficacy and tolerability of the typical doses of fenofibrate and niacin. METHODS: After an eight-week dietary run-in, 201 patients who had triglyceride (TG) levels of 150-499 mg/dL, high-density lipoprotein-cholesterol (HDL-C) levels of <45 mg/dL and low-density lipoprotein-cholesterol (LDL-C) levels of <130 mg/dL were randomly assigned to one of two treatment groups for 16 weeks: fenofibrate 160 mg or niacin extended release 1500 mg (starting at 500 mg and up-titrated at the fifth and ninth weeks). RESULTS: One hundred forty patients comp...
International audienceBACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular ...
Michel FarnierPoint Médical, Dijon, FranceAbstract: Mixed dyslipidemia is a common lipid diso...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...
BACKGROUND: The effectiveness of therapies that raise high-density lipoprotein cholesterol (HDL-C) ...
none6noINTRODUCTION: Fenofibrate is an effective and safe treatment for hypertriglyceridemia. How...
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 ...
Background: Low levels of plasma high-density lipoprotein cholesterol (HDL-C) represent an important...
Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels cont...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
Klaus G ParhoferMedical Department&nbsp;II Grosshadern, University of Munich, GermanyAbstract: A...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
OBJECTIVE: To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabe...
extending treatment beyond statins in the high-risk cardiovascular patient Gerald F Watts,1 Fredrik ...
Introduction: Choline fenofibrate is a newly developed choline salt of fenofibric acid, which is mor...
AbstractBackground:Plasma lipid abnormalities commonly persist in patients with diabetic dyslipidemi...
International audienceBACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular ...
Michel FarnierPoint Médical, Dijon, FranceAbstract: Mixed dyslipidemia is a common lipid diso...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...
BACKGROUND: The effectiveness of therapies that raise high-density lipoprotein cholesterol (HDL-C) ...
none6noINTRODUCTION: Fenofibrate is an effective and safe treatment for hypertriglyceridemia. How...
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 ...
Background: Low levels of plasma high-density lipoprotein cholesterol (HDL-C) represent an important...
Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels cont...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
Klaus G ParhoferMedical Department&nbsp;II Grosshadern, University of Munich, GermanyAbstract: A...
Aim: Niacin and fenofibrate are to date the most effective available HDL-C raising therapies. We exa...
OBJECTIVE: To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabe...
extending treatment beyond statins in the high-risk cardiovascular patient Gerald F Watts,1 Fredrik ...
Introduction: Choline fenofibrate is a newly developed choline salt of fenofibric acid, which is mor...
AbstractBackground:Plasma lipid abnormalities commonly persist in patients with diabetic dyslipidemi...
International audienceBACKGROUND: Niacin as an adjunct to statin treatment to reduce cardiovascular ...
Michel FarnierPoint Médical, Dijon, FranceAbstract: Mixed dyslipidemia is a common lipid diso...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...